SCHEMBL31048409

SCHEMBL31048409

CON=C1CCCc2cc(OC)cc(Br)c21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
MAPT P10636 3/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 2/20 0.34
EGFR P00533 4/20 0.33
XDH P47989 2/20 0.33
KIT P10721 2/20 0.33
PDGFRA P16234 2/20 0.33
FLT4 P35916 2/20 0.33
KDR P35968 2/20 0.33
FLT3 P36888 2/20 0.33
MEN1 O00255 1/20 0.33
NFE2L2 Q16236 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
MAOA P21397 1/20 0.33
BCL2 P10415 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31650059 1.00 ALDH1A1 (0.36) ALDH1A1MAPTMAPK1KMT2ATDP1
SCHEMBL25642895 1.00 ALDH1A1 (0.36) ALDH1A1MAPTMAPK1KMT2ATDP1
SCHEMBL31217238 0.86 ALDH1A1 (0.30) ALDH1A1
SCHEMBL34461299 0.85 PGR (0.43) ALDH1A1MAPTMAPK1KMT2ATDP1
SCHEMBL25305805 0.84 ALDH1A1 (0.36) ALDH1A1MAPTMAPK1KMT2ATDP1
SCHEMBL27183573 0.84 GAA (0.30) MAPTGAAHTT
SCHEMBL26059295 0.84 KDM4E (0.32) MAPTKDM4EGAAHTT
SCHEMBL30960102 0.84 ALDH1A1 (0.36) ALDH1A1MAPTMAPK1KMT2ATDP1
SCHEMBL30846777 0.84 GAA (0.30) MAPTGAAHTT
SCHEMBL31127801 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 US disclosed
WO-2025064542-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed
WO-2025011634-A1 PREPARATION METHOD FOR KRAS G12D INTERMEDIATE 上海森辉医药有限公司 2025-01-16 WO disclosed
WO-2024178304-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS ALDH1A1 4071/4885MAPT 3784/4885MAPK1 389/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS ALDH1A1 3593/4885MAPT 3604/4885MAPK1 297/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS ALDH1A1 3593/4885MAPT 3604/4885MAPK1 297/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS ALDH1A1 3593/4885MAPT 3604/4885MAPK1 297/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS ALDH1A1 1854/4885MAPT 3501/4885MAPK1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.